August 22, 2017 / 6:07 AM / 4 months ago

BRIEF-Sensorion's SENS-401 receives FDA orphan drug designation for treatment of cisplatin-induced ototoxicity in pediatric patients

Aug 22 (Reuters) - SENSORION SA:

* SENSORION ANNOUNCES FDA ORPHAN DRUG DESIGNATION GRANTED TO SENS-401 FOR TREATMENT OF CISPLATIN-INDUCED OTOTOXICITY IN PEDIATRIC PATIENTS

* SENSORION EXPECTS TO INITIATE A PHASE 2 CLINICAL TRIAL OF SENS-401 IN US AND EUROPE IN FIRST HALF OF 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below